Apr 29, 2019
Translarna(TM) (ataluren) is the First Therapy Approved in Brazil for Duchenne Muscular Dystrophy
Apr 18, 2019
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2019 Financial Results
Mar 04, 2019
PTC to Expand Product Portfolio in Latin America with WAYLIVRA(TM)
Mar 01, 2019
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 28, 2019
PTC Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides a Corporate Update
Feb 25, 2019
PTC Therapeutics Announces Partial Exercise of Underwriter's Option to Purchase Additional Shares
Feb 14, 2019
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2018 Financial Results
Feb 13, 2019
PTC Therapeutics Launches Fifth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy
Jan 31, 2019
PTC Therapeutics Launches New Program to Support Research Projects in Rare, Genetic Disorders
Jan 25, 2019
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 23, 2019
PTC Therapeutics Announces Pricing of Public Offering of Common Stock
Jan 22, 2019
PTC Therapeutics Announces Proposed Public Offering of Common Stock
Jan 07, 2019
PTC Therapeutics Provides Corporate Update and Outlines 5-year Strategic Plan at 2019 J.P. Morgan Healthcare Conference
Dec 20, 2018
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 18, 2018
PTC Therapeutics Deepens Financial and Commercial Expertise of Board with Two New Appointments
Nov 16, 2018
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 05, 2018
PTC Therapeutics Reports Third Quarter 2018 Financial Results and Provides a Corporate Update
Oct 23, 2018
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 22, 2018
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2018 Financial Results
Oct 06, 2018
PTC Therapeutics Announces Initial Data from Patient Registry Demonstrating Translarna(TM) (ataluren) Slows Disease Progression in Children with Duchenne Caused by a Nonsense Mutation